Skip to main content
    C

    Collplant Biotechnologies Ltd (CLGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.64
    -0.02 (-0.43%)

    Market Cap: $14.27M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Collplant Biotechnologies Ltd (CLGN) Earnings: Report Dates and Results

    Updated Sep 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Collplant Biotechnologies (CLGN) is expected to report earnings on Nov 24, 2026. In the quarter ended Jun 30, 2026, Collplant Biotechnologies reported EPS of -$1.89, above the -$2.40 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    21%(6/28)
    Avg Surprise
    -52.65%
    Streak
    1 Q

    Next Report

    CLGN has an expected report date of Nov 24, 2026.

    CLGN Earnings Call

    The latest CLGN earnings call transcript on file is labeled 2024Q3.

    Read the 2024Q3 transcript

    Earnings History

    Of the 28 quarters below that had an estimate, CLGN beat 6, missed 21 and matched 1. Revenue for the quarter ended Jun 30, 2026 was $108000, down 39.7% from $179000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$1.89-$2.40-$2.40 - -$2.40+21.25%BeatN/A10 up, 0 downSep 30, 2026$108000
    Mar 31, 2026-$0.23-$0.13N/A-72.51%MissN/A10 up, 0 downMay 29, 2026$73000
    Dec 31, 2025-$0.25-$0.19-$0.19 - -$0.19-31.58%MissN/A10 up, 1 downMar 26, 2026$60000
    Sep 30, 2025-$0.27$0.16-$0.07 - $0.38-268.75%MissN/A20 up, 1 downNov 26, 2025$77000
    Jun 30, 2025-$0.28-$0.10-$0.10 - -$0.10-180.00%MissN/A10 up, 1 downAug 20, 2025$179000
    Mar 31, 2025-$0.13-$0.04N/A-225.00%MissN/AN/A0 up, 0 downMay 28, 2025$2.06M
    Dec 31, 2024-$0.33-$0.28N/A-20.00%MissN/AN/A0 up, 0 downMar 26, 2025$164000
    Sep 30, 2024-$0.38-$0.28N/A-35.71%MissN/AN/A0 up, 0 downNov 27, 2024$4000
    Jun 30, 2024-$0.37-$0.27-$0.35 - -$0.19-37.04%Miss-175.5%20 up, 0 downAug 20, 2024$249000
    Mar 31, 2024-$0.37-$0.35-$0.35 - -$0.35-5.71%MissN/A10 up, 0 downApr 4, 2024$98000
    Dec 31, 2023-$0.24-$0.07-$0.38 - $0.24-242.86%MissN/A20 up, 0 downJan 25, 2024$299000
    Sep 30, 2023-$0.38$0.03-$0.45 - $0.41N/AN/AN/A30 up, 0 downNov 29, 2023$43000
    Jun 30, 2023$0.49$0.08-$0.41 - $0.44+512.50%BeatN/A20 up, 0 downAug 24, 2023$10.18M
    Mar 31, 2023-$0.33-$0.39-$0.39 - -$0.11+15.38%BeatN/A30 up, 0 downMay 24, 2023$433000
    Dec 31, 2022-$0.38-$0.31-$0.42 - -$0.21-22.58%MissN/A20 up, 0 downMar 29, 2023$58000
    Sep 30, 2022-$0.40$0.48N/A-183.33%MissN/A10 up, 0 downDec 1, 2022$109000
    Jun 30, 2022-$0.39-$0.08-$0.08 - -$0.08-387.50%MissN/A10 up, 0 downAug 25, 2022$66000
    Mar 31, 2022-$0.36-$0.14-$0.14 - -$0.14-157.14%Miss-140.9%10 up, 0 downMay 26, 2022$66000
    Dec 31, 2021-$0.30-$0.29-$0.29 - -$0.29-3.45%MissN/A10 up, 0 downMar 24, 2022$310000
    Sep 30, 2021-$0.29-$0.27-$0.29 - -$0.27-7.41%Miss-363.6%2N/ANov 18, 2021$140000
    Jun 30, 2021-$0.30-$0.27-$0.27 - $0.07-11.11%MissN/A2N/AAug 19, 2021$691000
    Mar 31, 2021$0.88$0.80$0.21 - $0.80+10.00%BeatN/A2N/AMay 27, 2021$14.50M
    Dec 31, 2020-$0.42-$0.30-$0.32 - -$0.28-40.00%MissN/A2N/AMar 26, 2021$557000
    Sep 30, 2020$0.11$1.96-$0.60 - $19.00-94.39%MissN/A2N/ADec 1, 2020$4.15M
    Jun 30, 2020-$0.20-$0.25-$0.25 - -$0.06+20.00%BeatN/A2N/AAug 28, 2020$823000
    Mar 31, 2020-$0.21-$0.45-$0.45 - -$0.01+53.33%BeatN/A2N/AApr 1, 2020$609000
    Dec 31, 2019-$0.86-$0.70N/A-22.86%MissN/A2N/AMar 18, 2020$439000
    Sep 30, 2019-$0.41-$0.26N/A-57.69%MissN/AN/AN/ANov 29, 2019$679000
    Jun 30, 2019-$0.17N/AN/AN/AN/AN/AN/A0 up, 0 downSep 26, 2019$606000
    Mar 31, 2019-$0.01-$0.01N/A0.00%In lineN/AN/A0 up, 0 downApr 1, 2019$594000
    Dec 31, 2018-$0.29N/AN/AN/AN/AN/AN/AN/AMar 31, 2019N/A
    Sep 30, 2018-$0.01N/AN/AN/AN/AN/AN/AN/ANov 29, 2018$225046
    Jun 30, 2018-$0.01N/AN/AN/AN/AN/AN/AN/ASep 21, 2018$178504
    Mar 31, 2018-$0.01N/AN/AN/AN/AN/AN/AN/AMay 24, 2018$221835
    Dec 31, 2017-$0.51N/AN/AN/AN/AN/AN/AN/AMar 21, 2018$273909
    Sep 30, 2017-$0.01N/AN/AN/AN/AN/AN/AN/ANov 20, 2017$74510
    Jun 30, 2017-$0.01N/AN/AN/AN/AN/AN/AN/ASep 1, 2017$57630
    Mar 31, 2017-$0.01N/AN/AN/AN/AN/AN/AN/AMay 29, 2017$69549
    Dec 31, 2016-$0.02N/AN/AN/AN/AN/AN/AN/AMar 27, 2017$51407
    Sep 30, 2016-$0.05N/AN/AN/AN/AN/AN/AN/ANov 24, 2016$24504
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.93, after -$1.45 the year before. It was -$0.11 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.93N/A
    Dec 31, 2024-$1.45N/A
    Dec 31, 2023-$0.46N/A
    Dec 31, 2022-$1.53N/A
    Dec 31, 2021-$0.01N/A
    Dec 31, 2020-$0.72N/A
    Dec 31, 2019-$1.45N/A
    Dec 31, 2018-$0.32N/A
    Dec 31, 2017-$0.54N/A
    Dec 31, 2016-$0.11N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2024Q3 for the period ended Sep 30, 2024, runs about 3,000 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q3Sep 30, 20242,9594
    2024Q2Jun 30, 20243,5186

    2024Q3 Earnings Call

    Opening remarks

    Dory Kurowski Moderator I would like to welcome everyone to CollPlant Biotechnologies Financial Results Conference Call to discuss the results for the third quarter ended September 30, 2024, where management will also provide a corporate business update. With us on the call today from CollPlant are Yehiel Tal, Chief Executive Officer, who will provide an overview of the company's programs and associated updates; and Eran Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of CollPlant financial results for the second quarter ending September 30, 2024. Both will be able to answer questions at the end of the call. Before we get started, I’d like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors including those set forth in the Risk Factors section of CollPlant's filings with the Securities and Exchange Commission. These filings can be found at www.sec.gov or on CollPlant's website at www.collplant.com. In addition, any forward-looking statements made on this call represent CollPlant's views only as of today, November 27, 2024, and should not be relied upon as representing the company's views as of any subsequent date. CollPlant's management specifically disclaims any obligation to update or revise any of these forward-looking statements. Finally, CollPlant management will refer to certain financial measures not reported in accordance with GAAP on this call. You can find reconciliations of these non-GAAP financial measures to the GAAP financial measures in the earnings press release that CollPlant published earlier today and which is available on CollPlant's website at ir.collplant.com. Now let me turn the call over to Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies. Please go ahead, sir.

    Yehiel Tal CEO Good morning, everyone, and thank you for joining us today on CollPlant's investor conference call to discuss our third quarter 2024 financial results and corporate development, as we pursue our mission to be a leader in the field of regenerative medicine. I will start with an update on the regenerative breast implant program. This quarter, we continued to advance our preclinical study that includes 200cc commercial-sized breast implants composed of our proprietary rhCollagen-based bioinks and printed with the Stratasys 3D printer. This study is critical to advancing our technology towards a marketed product and creating significant shareholder value. This most recent preclinical study launched in Q3 using clinical size implants has been designed to assess product performance and safety and is implementing a new and more suitable animal model, refined surgical protocol, and optimized implant design and formulation.

    Frequently Asked Questions About CLGN

    When is Collplant Biotechnologies's next earnings date?

    Collplant Biotechnologies's next earnings report is expected for Nov 24, 2026.

    Did CLGN beat earnings estimates last quarter?

    Yes. Collplant Biotechnologies reported EPS of -$1.89 for the quarter ended Jun 30, 2026, above the -$2.40 estimate, a 21.25% surprise.

    How often does CLGN beat earnings estimates?

    Collplant Biotechnologies beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -101.54%.